Copyright
©The Author(s) 2022.
World J Stem Cells. Oct 26, 2022; 14(10): 744-755
Published online Oct 26, 2022. doi: 10.4252/wjsc.v14.i10.744
Published online Oct 26, 2022. doi: 10.4252/wjsc.v14.i10.744
Main conditions | NCT number | Phase |
Osteoarthritis | NCT03818737 | Phase III |
Osteoarthritis | NCT02846675, NCT02967874 | Phase II |
Knee osteoarthritis | NCT04050111 | Phase II |
Knee osteoarthritis | NCT02276833, NCT04043819, NCT03940950 | Phase I |
Phase I | ||
Osteoarthritis | NCT03166410, NCT02697682, NCT02726945 | Preclinical |
Preclinical | ||
Knee osteoarthritis | NCT04440189, NCT02726945, NCT04440189 | Preclinical |
Preclinical |
Ref. | Treatment | Study type | Patients | Follow-up time | Outcome assessments | Consequences |
OA position/number | ||||||
Pak et al[41,42] (2016, 2018) | SVF + HA + PRP | Case report | 3 patients: 1 male, age: 68; 2 females, age: 60 and 87 | 3.5 mo | FRI, MRI, ROM, VAS | Cartilage repaired showed by MRI; all scores improved |
Knee | ||||||
Fodor et al[43] (2016) | SVF | Pilot study | 6 patients: 1 male, 5 females, mean age: 59 | 12 mo | ROM, WOMAC, VAS, TUG, MRI | All scores improved, no MRI evidence of cartilage regeneration |
NCT02357485 | Knee/8 OA | |||||
Yokota et al[44] (2017) | SVF | Case report | 13 patients: 2 males, 11 females, mean age: 74.5 | 6 mo | VAS, JKOM, WOMAC | All scores improved |
Knee/26 OA | ||||||
Nguyen et al[45] (2017) | AM vs AM + SVF + PRP | Comparative study | 30 patients (15 per group: 3 males, 12 females) mean age: 58 | 18 mo | VAS, Lysholm, WOMAC, MRI | All scores improved compared with AM group; AM + SVF + PRP group had obvious cartilage repair show by MRI |
NCT02142842 | Knee | |||||
Michalek et al[46] (2017) | SVF | Case control multi-centric non-randomized study | 1128 patients: 596 males, 532 females, median age: 62 | 17.2 mo | Modified KOOS/HOOS | KOOS/HOOS improved, most patients gradually improved, obesity and more severe OA healed slowly |
Knee and hip/1856 OA | ||||||
Tantuway et al[47] (2017) | SVF | Case report | 101 patients: 41 males, 60 females, age: 29-84 | 3-24 mo | KOOS | KOOS and joint function improved, pain relieved, patients could move normally |
Knee/201 OA | ||||||
Russo et al[48,49] (2017, 2018) | SVF | Retrospective study | 30 patients: 21 males, 9 females, median age: 43 | 12-36 mo | Lysholm, VAS, IKDC-subjective, KOOS | 41%, 55%, 55%, 64% of the patients improved in the scores, respectively |
Diffuse degenerative keen | ||||||
Bright et al[50] (2018) | SVF | Case report | 1 patient: female, age: 27 | 3 yr | WOMAC, HOOS | Symptoms of OA reduced, all scores improved, ankylosing spondylitis, depression, anxiety and fatigue improved |
Knee and hip | ||||||
Barfod et al[51] (2019) | SVF | Prospective cohort study | 20 patients, mean age: 49 | 12 mo | KOOS | KOOS improved |
NCT02697682 | Knee | |||||
Roato et al[52] (2019) | SVF | Case report | 20 patients: 9 males, 11 females, mean age: 59.6 | 18 mo | VAS, WOMAC | Pain relieved, scores improved |
Knee | ||||||
Hudetz et al[53] (2019) | SVF | Prospective, non-randomized and single center study | 20 patients: 15 males, 5 females | 12 mo | VAS, WOMAC, KOOS | All scores improved, pain and symptoms relieved for up to a year |
Knee | ||||||
Berman et al[54] (2019) | SVF | Case report | 2586 patients | 2-5 yr | Questionnaire (visual acuity pain scores, sustained improvement in function) | Over 80% of patients' pain relieved, joint function improved and maintain 1 yr; outcomes between male and female or between SVF alone and SVF + PRP showed no difference |
NCT10953523 | Knee | |||||
Michalek et al[55] (2019) | SVF | Multicenter case-control study | 29 patients: 9 males, 20 females, mean age: 83.3 | 36 mo | Modified KOOS/HOOS | Apart from 3 elderly patients died from aging, other patients' pain and weekly dosage of analgesics were reduced, KOOS/HOOS improved |
Knee and hip | ||||||
Yokota et al[56] (2019) | ADSC vs SVF | Retrospective cohort study | ADSC: 42 patients; SVF: 38 patients | 6 mo | VAS, KOOS | No major complications occurred, knee joint effusion was more likely to occur in SVF group than ADSC group (SVF 8%, ADSC 2%); VAS and KOOS improved in both groups |
Knee/128 OA | ||||||
Mayoly et al[57] (2019) | SVF +PRP | Case report | 3 patients: 1 male, 2 females, mean age: 62 | 12 mo | VAS, PRWE, DASH | All scores improved |
NCT03164122 | Wrist | |||||
Hong et al[58] (2019) | SVF vs HA | Double-blind randomized self-controlled trial | 16 patients (with bilateral symptomatic knee OA) one side: SVF, the other side: HA. 3 males, 13 females, mean age: 52 | 12 mo | VAS, WOMAC, ROM, MRI (MOCART, WORMS) | Significant improvement of VAS, WOMAC and ROM in SVF group, but no improvement in HA group; SVF group was superior to HA group in cartilage repair showed by MOCART and WORMS |
Knee | ||||||
Tran et al[59] (2019) | SVF + AM vs AM | Single-center, non-randomized, placebo-controlled study | 33 patients, placebo group (AM): 3 males, 12 females, mean age: 58.2; SVF group (SVF + AM): 5 males, 13 females, mean age: 59 | 24 mo | VAS, WOMAC, Lysholm, OS | VAS, WOMAC of SVF group reduced significantly compared with placebo group, and maintained 24 mo; Lysholm, OS of SVF group improved |
Knee | ||||||
Garza et al[60] (2020) | SVF | Double-blinded prospective randomized controlled study | 39 patients (randomly assigned to high-, low-dose SVF, or placebo at 1:1:1) | 12 mo | WOMAC, MRI | Symptoms and pain relieved by SVF treatment for up to at least 12 mo; changes in WOMAC scores reached statistical significance in the high- and low-dose groups compared to the placebo group; the improvements were dose dependent |
NCT02726945 | Knee | |||||
Lapuente et al[61] (2020) | SVF | Retrospective study | 50 patients: 28 males, 22 females, age: 50-89 | 12 mo | Lequesne, WOMAC, VAS | All scores improved |
Knee/100 OA | ||||||
Tsubosaka et al[62] (2020) | SVF | Case report | 57 patients: 41 males, 16 females, mean age: 69.4 | 13.7 mo | ROM, WOMAC, VAS, KOOS, MRI | WOMAC, VAS and KOOS improved, while no significant difference in hip-knee-ankle angle, T2 mapping values of lateral femur and tibia improved significantly |
Knee |
- Citation: Tang Q, Zhao XS, Guo A, Cui RT, Song HL, Qi ZY, Pan Y, Yang Y, Zhang FF, Jin L. Therapeutic applications of adipose-derived stromal vascular fractions in osteoarthritis. World J Stem Cells 2022; 14(10): 744-755
- URL: https://www.wjgnet.com/1948-0210/full/v14/i10/744.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v14.i10.744